This site uses cookies to store information on your computer. Learn more x

DSM Managing Board re-appointments

Heerlen, NL, 18 Mar 2015 08:15 CET

Royal DSM, the global Life Sciences and Materials Sciences company, today announces the proposed re-appointment of Stephan B. Tanda as member of the DSM Managing Board at the upcoming Annual General Meeting of Shareholders (AGM) on 30 April 2015. DSM also announces the departure of DSM Managing Board member Stefan Doboczky per 1 June 2015.

The transformation of the DSM pharmaceutical activities was completed in 2014, and DSM now holds participations in two joint ventures. As a result, it has been agreed between DSM and Stefan Doboczky that his term as a Managing Board member will not be renewed at the upcoming AGM. Stefan will leave DSM per 1 June and has accepted employment outside of DSM.

Stefan Doboczky has worked in DSM’s Pharma businesses for 17 years and has, as a Managing Board member, successfully led the design and execution of the Pharma strategy, resulting in the creation of DSM Sinochem Pharmaceuticals (DSP, Antibiotics JV with Sinochem) and DPx (Pharma JV with JLL/Patheon).

The responsibilities of Stefan Doboczky will be redistributed among the current Managing Board members.

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: “During the years that Stefan worked for DSM in Pharma and as Regional President in Asia, he spearheaded many strategic growth initiatives that helped transform our business. DSM is very grateful for the contribution he has made over many years and, also on behalf of my colleagues, I wish him every success in the next step in his career.”